Synthesis of substituted pyrimidinedione derivatives as potential schistosomicidal agents

Letters in Drug Design and Discovery

Volumn 6, Issue 4, 2009, Pages 268-277

  Saudi, Manal N S ^a   Youssef, Amal M ^a   Badr, Mona H ^a   Elbayaa, Rasha Y ^a   El azzouni, Mervat Z ^b   Mossallam, Shereen F ^b   Baddour, Nahed M ^c   Eissa, Maha M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Praziquantel; Schistosomicidal activity; Tetrahydropyrimidinediones

Indexed keywords

2 (2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL)ISOINDOLINE 1,3 DIONE; 6 (1H BENZIMIDAZOLE 2 YLAMINO)PYRIMIDINE 2,4 (1H,3H) DIONE; 6 [(1H BENZIMIDAZOLE 2 YL)METHYLAMINO]PYRIDINE 2,4 (1H,3H) DIONE; ANTISCHISTOSOMAL AGENT; ETHYL (2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL)IMIDOFORMATE; ETHYL [N (1H BENZIMIDAZOLE 2 YL) N (2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL)AMINO]ACETATE; N' (2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) N (2 HYDROXY 2 METHYLPROPYL)IMIDOFORMAMIDE; N,N' BIS(2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL)IMIDOFORMAMIDE; PRAZIQUANTEL; TETRAHYDROPYRIMIDINEDIONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHELMINTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTEGUMENT; LIVER GRANULOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE; WORM EGG;

EID: 66349098330     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018009788452546     Document Type: Article

References (43)

1. King, C.H.; Dickman, K.; Tisch, D.J. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet, 2005, 365, 1561-1569. (Pubitemid 40615405)
2. Chitsulo, L.; Engels, D.; Montresor, A.; Savioli, L. The global status of schistosomiasis and its control. Acta Trop., 2000, 77, 41-51.
3. WHO. Report of the scientific working group on schistosomiasis, 2005. Geneva: TDR/World Health Organization, 2006.
4. Van der Werf, M.J.; De Vlas, S.J.; Brooker, S.; Looman, C.W.; Nagelkerke, N.J.; Habbema, J.D.; Engels, D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop., 2003, 86, 125-139. (Pubitemid 36561364)
5. Bergquist, N. R. Schistosomiasis: from risk assessment to control. Trends Parasitol., 2002, 18, 309-314.
6. Pearce, E.J. Progress towards a vaccine for schistosomiasis. Acta Trop., 2003, 86(2-3), 309-313. (Pubitemid 36561374)
7. Gönnert, R.; Andrews, P. Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd., 1977, 52, 129-150.
8. Cioli, D.; Pica-Mattoccia, L.; Archer, S. Antischistosomal drugs: past, present and future? Pharmacol. Ther., 1995, 68, 35-85.
9. Doenhoff, M.; Kimani, G.; Cioli, D. Praziquantel and the control of schistosomiasis. Parasitol. Today, 2000, 16, 364-366.
10. Colley, D.G.; LoVerde, P.T.; Savioli, L. Medical helminthology in the 21st century. Science, 2001, 293,1437-1438.
11. Fallon, P.G.; Sturrock, R.F.; Niang, A.C.; Doenhoff, M.J. Short report: diminished susceptibility to praziquantel in a senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg., 1995, 53, 61-62.
12. Fallon, P.G.; Doenhoff, M.J. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg., 1994, 51, 83-88. (Pubitemid 24266292)
13. Cioli, D. Praziquantel: is there real resistance and are there alternatives? Curr. Opin. Infect. Dis., 2000, 13, 659-663.
14. Sariri, R.; Khalili, G. Synthesis of purine antiviral agents, hypoxanthine and 6-mercaptopurine. Russ. J. Org. Chem., 2002, 38(7), 1096-1098. (Pubitemid 37116735)
15. Cingolani, G.M.; Giardina, D.; Carotti, A.; Casini, G.; Ferappi, M. Pthalimide derivatives of pyrimidine and thiazole heterocycles. Farmaco, 1976, 31(2),133-139.
16. Ismail, M.; Botros, S.; Metwally, A.; William, S.; Farghally, A.; Tao, L.F.; Day, T.A.; Bennett, J.L. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg., 1999, 60(6), 932-935. (Pubitemid 29296217)
17. Botros, S.; William, S.; Hammam, O.; Zídek, Z.; Holý, A. Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine against Schistosomiasis mansoni in mice. Antimicrob. Agents Chemother., 2003, 47(12), 3853-3858. (Pubitemid 37485000)
18. Smithers, S.R.; Terry, R.J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology, 1965, 55(4), 695-700.
19. Mahran, M.A.; William, S.; Ramzy, F.; Sembel, A.M. Synthesis and in vitro evaluation of new benzothiazole derivatives as schistosomicidal agents. Molecules, 2007, 12(3), 622-633.
20. Katz, N.; Dias, E.P.; Souza, C.P.; Bruce, J.I.; Coles, G.C. Rate of action of schistosomicides in mice infected with Schistosoma mansoni. Rev. Soc. Bras. Med. Trop., 1989, 22, 183-186.
21. Yole, D.S.; Reid, G.D.F.; Wilson, A. Protection against Schistosoma mansoni and associated immune response in the vervet monkey Cercopithecus aethiopicus by irradiated cercariae vaccine. Am. J. Trop. Med. Hyg., 1996, 54(3), 265-270. (Pubitemid 26100713)
22. Cheever, A.W. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull. World Health Organ., 1968, 39(2), 328-331.
23. Shaw, M.K.; Erasmus, D.A. Schistosoma mansoni: structural damage and tegumental repair after in vivo treatment with praziquantel. Parasitology, 1987, 94 (2), 243-254. (Pubitemid 17043463)
24. Cioli, D.; Pica-Mattoccia, L. Praziquantel. Parasitol. Res., 2003, 90, 53-59.
25. Kumar, V.; Gryseels, B. Use of Praziquantel against schistosomiasis: a review of the current status. Int. J. Antimicrob. Agents, 1994, 4, 313-320. (Pubitemid 24334166)
26. Utzinger, J.; Goran, E. K. N.; Dri, A. N.; Lengeler, C.; Tanner, M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration on intensity of infection. Trop. Med. Int. Health, 2000, 5, 771-778. (Pubitemid 32001036)
27. Wolde Mussie, E.; VandeWaa, J.; Pax, R.A.; Fetterer, R.; Bennett, J.L. Schistosoma mansoni: calcium efflux and effects of calcium-free media on responses of the adult male musculature to praziquantel and other agent-inducing contractions. J. Parasitol., 1982, 68, 48-52.
28. Pax, R.; Bennett, J.L.; Fetterer, R. A benzodiazepine derivative and praziquantel: Effects on musculature of Schistosoma mansoni and Schistosoma japonicum Naunyn-Schmiedebergs. Arch. Pharmacol., 1978, 304, 309-314. (Pubitemid 9060920)
29. Bricker, C.S.; Depenbusch, J.W.; Bennett, J.L. Tegumental disruption of S. mansoni caused by praziquantel and Ro 11- 3128. Z Parasitenk, 1983, 69, 61-71.
30. th International Congress of Chemotheraphy, vol.1, American Society for Microbiology: Washingtin DC, 1978, pp. 147-148.
31. Smith, J.H.; Reynolds, E.S.; Von Lichtenberg, F. The integument of Schistosoma mansoni. Am. J. Trop. Med. Hyg., 1969, 18, 28-49.
32. Hockley, D.J. Ultrastructure of the tegument of Schistosoma. Adv. Parasitol., 1973, 11, 233-305.
33. Erasmus, D.A. Schistosoma mansoni: development of the vitelline cell, its role in drug sequestration, and changes induced by Astiban. Exp. Parasitol., 1975, 38, 240-256.
34. Pappas, P.W.; Read, C.P. Membrane transport in helminth parasites: a review. Exp. Parasitol., 1975, 37, 469-530.
35. Mandour, M.E.; el Turabi, H.M.; Homeida, M.; el Sadig, T.; Ali, H.M.; Bennett, J.L.; Leahey, W.J.; Harron, D.W. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg., 1990, 84, 389-393.
36. Castro, N.; Medina, R.; Sotelo, J.; Jung, H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother., 2000, 44, 2903-2904.
37. Castro, N.; Jung, H.; Medina, R.; González-Esquivel, D.; Lopez, M.; Sotelo, J. Interaction between grapefruit juice and praziquantel in humans. Antimicrob. Agents Chemother., 2002, 46, 1614-1616. (Pubitemid 34415362)
38. Mourao, S.C.; Costa, P.I.; Salgado, H.R.; Gremiao, M.P. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int. J. Pharm., 2005, 295, 157-162. (Pubitemid 40558798)
39. Metwally, A.; Bennett, J.L.; Botros, S.; Ebeid, F.; Attar, G.D.M. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacol. Res., 1995, 31, 53-59.
40. Van Lieshout, L.; Stelma, F.F.; Guisse, F.; Falcao, S.T.; Ferreira, S.T.; Polman, K.; Van Dam, G.J.; Diakhate, M.; Sow, S.; Deelder, A.; Gryseels, B. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am. J. Trop. Med. Hyg., 1999, 61, 760-765.
41. Brindley, P.J.; Sher, A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J. Immunol., 1987, 139, 215-220. (Pubitemid 17091787)
42. Doenhoff, M.J.; Modha, J.; Lambertucci, J.R. Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite esterase. Immunology, 1988, 65, 507-510. (Pubitemid 19031202)
43. Harnett, W.; Kusel, J. R. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology, 1986, 93, 401-405. (Pubitemid 16031097)